PTC Therapeutics Plans to Offer $500M Convertible Senior Notes
PTC Therapeutics announced that it intends to offer $500M aggregate principal amount of Convertible Senior Notes due 2031 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
